	NOV 0 5 2007						
FORM WAS 4440 (Aug P (modified PTO/SP/08)			LPTO/SB/08)	APPLICATION NO.:	09/485,005	ATTY. DOCKET NO.: V0179.70001US00	
FORM B (modified PTO/SB/08)  INFORMATION DISCLOSURE				FILING DATE: 2000	September 11,	CONFIRMATION NO.: 1379	
STATEMENT BY APPLICANT				APPLICANT:	Erich Wanker et al.		
				GROUP ART UNIT:	1641	EXAMINER: G. Gabe	G. Gabel
Sheet	1	of	1	GROUP ART UNIT.	1041	EAAMINEK:	G. Gabei

## U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or Issue	
Initials #	No.	Number	Kind Code	Document Document	of Cited Document MM-DD-YYYY	

## FOREIGN PATENT DOCUMENTS

Examiner's	Cite	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	- Name of Patentee or Applicant of Cited Publication Document Cited Docum MM-DD-YY		(Y/N)
		wo	99/06545		Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	02-11-1999	

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Millipore Webpage, Immobilon™ Transfer Membranes: for superior protein and nucleic acid blots.	
		Millipore Webpage, Immobilon™-P Transfer Membrane, Introduction.	
		ATHANASOU, N.A. Dialysis Amyloid, Chapter 8: Description, localization, and progression of β2-microglobulin dialysis-related amyloid deposition. 1996; 173-191.	
		KELLY, J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol. 1996 Feb;6(1):11-7.	
		PERLER, F.B. et al., Compilation and analysis of intein sequences. Nucleic Acids Res. 1997 Mar 15;25(6):1087-93.	
		WANKER, E.E. and DROGE, A. Huntington's Disease, 3 <sup>rd</sup> Edition, Chapter 11: Structural Biology of Huntington's Disease 2002;327-340.	

EXAMINER:	DATE CONSIDERED:

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 12870G163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>\*</sup>a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).